# Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

> **NCT04066764** · PHASE3 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 200 (estimated)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Warfarin
- **DRUG:** Nadroparin

## Key facts

- **NCT ID:** NCT04066764
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-08
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04066764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04066764, "Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04066764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*